https://www.curevac.com/en/about-us/ https://www.curevac.com/en/about-us/partnerships/ https://www.curevac.com/en/technology/ https://www.curevac.com/en/technology/production/ https://www.curevac.com/en/technology/publications/ https://www.curevac.com/en/pipeline/ https://www.curevac.com/en/newsroom/news/ https://www.curevac.com/en/investor-relations/overview/ https://www.curevac.com/en/investor-relations/financial-reports/
HUGE DROP IN SHARES 06-16-2021 A.H. OVER $50
DROP TO $38
About 11 mil. left for trading 3-1/2 % are shorted What Type Of Shareholders Own The Most Number of CureVac N.V. (NASDAQ:CVAC) Shares?
Simply Wall St
Insider Own 55.92%
Inst Own 23.40%
Shs Outstand 177.97M
Shs Float 82.25M
Short Float 3.59%
The big shareholder groups in CureVac N.V. (NASDAQ:CVAC) have power over the company. Large companies usually have institutions as shareholders,
and we usually see insiders owning shares in smaller companies.
Warren Buffett said that he likes "a business with enduring competitive advantages that is run by able and owner-oriented people."
So it's nice to see some insider ownership, because it may suggest that management is owner-oriented.
With a market capitalization of US$21b, CureVac is rather large. We'd expect to see institutional investors on the register.
Companies of this size are usually well known to retail investors, too.
Taking a look at our data on the ownership groups (below), it seems that institutions are noticeable on the share registry.
Let's delve deeper into each type of owner, to discover more about CureVac.
View our latest analysis for CureVac
What Does The Institutional Ownership Tell Us About CureVac?
Institutional investors commonly compare their own returns to the returns of a commonly followed index.
So they generally do consider buying larger companies that are included in the relevant benchmark index.
As you can see, institutional investors have a fair amount of stake in CureVac.
This can indicate that the company has a certain degree of credibility in the investment community.
However, it is best to be wary of relying on the supposed validation that comes with institutional investors. They too, get it wrong sometimes.
When multiple institutions own a stock, there's always a risk that they are in a 'crowded trade'.
When such a trade goes wrong, multiple parties may compete to sell stock fast. This risk is higher in a company without a history of growth.
You can see CureVac's historic earnings and revenue below, but keep in mind there's always more to the story.
CureVac is not owned by hedge funds. Looking at our data, we can see that the largest shareholder is dievini Hopp BioTech holding GmbH & Co. KG with 42% of shares outstanding.
KfW, Asset Management Arm is the second largest shareholder owning 16% of common stock, and GlaxoSmithKline plc holds about 8.0% of the company stock.
https://www.curevac.com/about-curevac https://www.curevac.com/what-we-do https://www.curevac.com/our-pipeline https://www.curevac.com/partnering
A more detailed study of the shareholder registry showed us that 2 of the top shareholders have a considerable amount of ownership in the company, via their 58% stake.
Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments.
There are a reasonable number of analysts covering the stock, so it might be useful to find out their aggregate view on the future.
Insider Ownership Of CureVac
The definition of company insiders can be subjective and does vary between jurisdictions. Our data reflects individual insiders, capturing board members at the very least.
Company management run the business, but the CEO will answer to the board, even if he or she is a member of it.
Insider ownership is positive when it signals leadership are thinking like the true owners of the company.
However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances.
We can see that insiders own shares in CureVac N.V.. It is a very large company, and board members collectively own US$1.1b worth of shares (at current prices).
It is good to see this level of investment. You can check here to see if those insiders have been buying recently.
General Public Ownership
With a 21% ownership, the general public have some degree of sway over CureVac. While this group can't necessarily call the shots,
it can certainly have a real influence on how the company is run.
CureVac has entered into a collaboration with Arcturus Therapeutics Ltd. (NASDAQ:ARCT), an RNA medicines company,
to access the full suite of Arcturus’ lipid-mediated delivery intellectual property to enable the development of mRNA product candidates.
CureVac Announces Pricing of Initial Public Offering
"" rel="nofollow ugc" target="_blank">https://www.curevac.com/news/curevac-announces-pricing-of-initial-public-offering"
; style="box-sizing: border-box; -webkit-tap-highlight-color: transparent; outline: 0px; color: rgb(241, 110, 48); text-decoration-line: none; background-color: transparent; font-family: "Open Sans", sans-serif; font-weight: 600; margin-right: 20px; line-height: 22px;" target="_blank" rel="nofollow ugc">
Email Press Release PDF version
TÜBINGEN, Germany/ BOSTON, USA – August 14, 2020 – CureVac B.V. (“CureVac” or the “Company”), a clinical-stage biopharmaceutical company
developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), announced today the pricing of its
initial public offering of 13,333,333 common shares at an initial public offering price of $16.00 per common share, for total gross proceeds of approximately $213.3 million.
In addition, the Company has granted the underwriters a 30-day option to purchase up to an
additional 1,999,999 common shares at the public offering price, less underwriting discounts and commissions. All of the common shares are being offered by CureVac.
The shares are scheduled to begin trading on the Nasdaq Global Market today, August 14, 2020, under the ticker symbol “CVAC.”
The offering is expected to close on August 18, 2020, subject to customary closing conditions.
BofA Securities, Jefferies and Credit Suisse are acting as joint book-running managers for the proposed offering, with Berenberg and Kempen & Co acting as passive book-running managers.
A registration statement relating to these securities was declared effective by the Securities and Exchange Commission (“SEC”) on August 13, 2020.
The offering is being made only by means of a prospectus. Copies of the final prospectus relating to the offering may be obtained, when available,
for free by visiting EDGAR on the SEC website at www.sec.gov. Alternatively, copies of the final prospectus, when available, may be obtained from
BofA Securities, Attention: Prospectus Department, NC1-004-03-43, 200 North College Street, 3rd Floor, Charlotte, NC 28255-0001,
by telephone at (800) 299-1322 or by email at firstname.lastname@example.org; Jefferies LLC, Attention:
Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by telephone at (877) 821-7388 or by email at Prospectus_Department@Jefferies.com;
and Credit Suisse Securities (USA) LLC, Attention: Prospectus Department, 6933 Louis Stephens Drive, Morrisville, North Carolina 27560, by telephone at (800) 221-1037 or by email at email@example.com.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities,
nor shall there be any sale of these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
CureVac is a global clinical-stage biopharmaceutical company in the field of messenger RNA (mRNA) technology with expertise in developing
and optimizing this versatile molecule for medical purposes.
The principle of CureVac's proprietary technology is the use of mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases.
The company applies its technologies for the development of prophylactic vaccines, cancer therapies,
antibody therapies and the treatment of protein therapies. CureVac is headquartered in Tübingen, Germany with sites in Frankfurt and Boston, USA.
CureVac Investor Relation Contact
Dr. Sarah Fakih, Vice President Investor Relations
CureVac, Tübingen, Germany
T: +49 7071 9883-1298
M: +49 160 90 496949
CureVac Media Contact
Thorsten Schüller, Director Corporate Communications
CureVac, Tübingen, Germany
T: +49 7071 9883-1577
*DISCLAIMER *The Board Monitor and The Board Assistants herewith, are not licensed brokers and assume NO responsibility for the actions, investment decisions, and or messages posted on this forum.
• We do NOT recommend that anyone buy or sell any securities posted herewith. Any trade entered into risks the possibility of losing the funds invested.
• There are no guarantees when buying or selling any security.